No pharmaceutical opinion available for this interaction.
Ritonavir can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Glyburide.
Ritonavir can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glyburide.
3A4 and 2D6 (major), 1A2 and 2B6 (minor), 5 metabolites, one of which has a weak concentration of an active metabolite (M-2), transporters: MRP1, MRP2, P-gp
2B6, 2C8, 2C9, 1A2, 2C19 (moderate) UGT (moderate)
3A4 (potent) and 2D6 (moderate), transporters: BCRP, OATP1A2, OATP1B1, OATP1B3, MRP1, MRP2, OCT1, OCT2, P-gp
2C9 and 3A4
Possible increase of the hypoglycemic effect.
Possible decrease of clinical efficacy.
Monitor the clinical efficacy and appearance of adverse effects.
Adjust dosage if necessary.
Metformin, DPP-4 Inhibitors, GLP-1 Agonists
Signs and symptoms of hypoglycemia : headache, dizziness, tiredness, rapid heartbeat, nervousness, shakiness, nausea and sweating.